Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates

DEGROOT, A; MCMURRY, J; MOISE, L

doi:10.1016/j.coph.2008.08.002

Cited by 109vaccines and immunoinformatics approachesBiosimilars and Bioanalytical MethodsMonoclonal and Polyclonal Antibodies Research

Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates

DEGROOT, A, MCMURRY, J, MOISE, L·2008·Current Opinion in Pharmacology

DOI 10.1016/j.coph.2008.08.002

Open this paper in CoChat — free account

Abstract

Immunogenicity can be a major obstacle to successful protein drug therapy. Antidrug antibodies may neutralize therapeutic function, influence pharmacokinetics and, in some cases, lead to severe adverse effects. These effects depend on factors including dose, regimen, delivery route and contaminants, among others. Importantly, immunogenicity is a consideration that is better addressed during preclinical development before complications arise in clinical trials or following licensure. This article will address the development and application of computational tools for immunogenicity assessment of protein therapeutics, and validation of those predictions using peripheral blood from exposed subjects or alternative in vivo methods.

Integrity signals

Registry

Crossref · 10.1016/j.coph.2008.08.002

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

There are efforts aimed at predicting immunogenicity using in silico and in vitro tools.
“Despite these challenges, there are efforts aimed at predicting immunogenicity using in silico and in vitro tools.49”
From Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development (2018) · cites this paper as [49]

NOD/SCID/γcnull mouse: an excellent recipient mouse model for engraftment of human cells
Ito, M., Hiramatsu, H., Kobayashi, K., Suzue, K., Kawahata, M., Hioki, K., Ueyama, Y., Koyanagi, Y., Sugamura, K., Tsuji, K., et al. (2002) · Blood · doi:10.1182/blood-2001-12-0207 · Cited by 1,483 · see citing works
Natural versus adaptive regulatory T cells
Bluestone, J. A., & Abbas, A. K. (2003) · Nature reviews. Immunology · doi:10.1038/nri1032 · Cited by 1,319 · see citing works
Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin
Casadevall, N., Nataf, J., Viron, B. M., Kolta, A. M., Kiladjian, J., Martin-Dupont, P., Michaud, P. A., Papo, T., Ugo, V., Teyssandier, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011931 · Cited by 1,244 · see citing works
Multiple defects in innate and adaptive immunologic function in NOD/LtSz- scid mice.
Shultz, L. D., Schweitzer, P. A., Christianson, S. W., Gott, B., Schweitzer, I. B., Tennent, B. J., McKenna, S., Mobraaten, L. E., Rajan, T. V., Greiner, D. L., et al. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.1.180 · Cited by 1,224 · see citing works
Development of a Human Adaptive Immune System in Cord Blood Cell-Transplanted Mice
Traggiai, E., Chicha, L., Mazzucchelli, L., Bronz, L., Piffaretti, J.-C., Lanzavecchia, A., & Manz, M. G. (2004) · Science · doi:10.1126/science.1093933 · Cited by 989 · see citing works
Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chainnull mice
Ishikawa, F., Yasukawa, M., Lyons, B. L., Yoshida, S., Miyamoto, T., Yoshimoto, G., Watanabe, T., Akashi, K., Shultz, L. D., & Harada, M. (2005) · Blood · doi:10.1182/blood-2005-02-0516 · Cited by 933 · see citing works
Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires
Southwood, S., Sidney, J., Kondo, A., del Guercio, M., Appella, E., Hoffman, S. L., Kubo, R. T., Chesnut, R. W., Grey, H. M., & Sette, A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.7.3363 · Cited by 665 · see citing works
Immunogenicity of protein therapeutics
Groot, A. S. D., & Scott, D. W. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.07.011 · Cited by 545 · see citing works
Activation of natural regulatory T cells by IgG Fc–derived peptide “Tregitopes”
Groot, A. S. D., Moise, L., McMurry, J. A., Wambre, E. R., Overtvelt, L. V., Moingeon, P. E., Scott, D. W., & Martin, W. D. (2008) · Blood · doi:10.1182/blood-2008-02-138073 · Cited by 392 · see citing works
Self-citation
A Novel Mechanism of Action for Anti-Thymocyte Globulin
Lopez, M., Clarkson, M. R., Albin, M., Sayegh, M. H., & Najafian, N. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006050422 · Cited by 365 · see citing works
Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products.
Koren, E., Smith, H. W., Shores, E., Shankar, G., Finco-Kent, D., Rup, B., Barrett, Y., Devanarayan, V., Gorovits, B., Gupta, S., et al. (2008) · JIM - Journal of Immunological Methods · doi:10.1016/j.jim.2008.01.001 · Cited by 332 · see citing works
CEP: a conformational epitope prediction server
Kulkarni‐Kale, U., Bhosle, S. G., & Kolaskar, A. S. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki460 · Cited by 299 · see citing works
Viral immune evasion: a masterpiece of evolution
Vossen, M. T., Westerhout, E. M., Söderberg-Nauclér, C., & Wiertz, E. (2002) · Immunogenetics · doi:10.1007/s00251-002-0493-1 · Cited by 279 · see citing works
Immune Responses to Therapeutic Proteins in Humans - Clinical Significance, Assessment and Prediction
Koren, E., Zuckerman, L., & Mire‐Sluis, A. R. (2002) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201023378175 · Cited by 267 · see citing works
Creation of “Humanized” Mice to Study Human Immunity
Pearson, T., Greiner, D. L., & Shultz, L. D. (2008) · Current Protocols in Immunology · doi:10.1002/0471142735.im1521s81 · Cited by 214 · see citing works
Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide
Steere, A., Klitz, W., Drouin, E. E., Falk, B., Kwok, W., Nepom, G., & Lee, A. B.-L. (2006) · Journal of Experimental Medicine · doi:10.1084/jem.20052471 · Cited by 207 · see citing works
Detection of GAD65-Specific T-Cells by Major Histocompatibility Complex Class II Tetramers in Type 1 Diabetic Patients and At-Risk Subjects
Reijonen, H., Novak, E. J., Kochik, S. A., Heninger, A., Liu, A. W., Kwok, W. W., & Nepom, G. T. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1375 · Cited by 201 · see citing works
Antibody Response to Aggregated Human Interferon Alpha2b in Wild-type and Transgenic Immune Tolerant Mice Depends on Type and Level of Aggregation
Hermeling, S., Schellekens, H., Maas, C., Gebbink, M. F. B. G., Crommelin, D. J. A., & Jiskoot, W. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20599 · Cited by 185 · see citing works
CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1.
Shirai, M., Arichi, T., Nishioka, M., Nomura, T., Ikeda, K., Kawanishi, K., Engelhard, V. H., Feinstone, S. M., & Berzofsky, J. A. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.6.2733 · Cited by 165 · see citing works
Utilization of MHC Class I Transgenic Mice for Development of Minigene DNA Vaccines Encoding Multiple HLA-Restricted CTL Epitopes
Ishioka, G. Y., Fikes, J. D., Hermanson, G., Livingston, B. D., Crimi, C., Qin, M., del Guercio, M., Oseroff, C., Dahlberg, C. M., Alexander, J., et al. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.7.3915 · Cited by 164 · see citing works
NOD/LtSz- Rag1 null Mice: An Immunodeficient and Radioresistant Model for Engraftment of Human Hematolymphoid Cells, HIV Infection, and Adoptive Transfer of NOD Mouse Diabetogenic T Cells
Shultz, L. D., Lang, P. A., Christianson, S. W., Gott, B., Lyons, B. L., Umeda, S., Leiter, E. H., Hesselton, R., Wagar, E. J., Leif, J., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.5.2496 · Cited by 160 · see citing works
Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines
Livingston, B. D., Newman, M. J., Crimi, C., McKinney, D. M., Chesnut, R. W., & Sette, A. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00233-x · Cited by 155 · see citing works
Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences
Meister, G. T. (1995) · Vaccine · doi:10.1016/0264-410x(94)00014-e · Cited by 155 · see citing works
Immunomics: discovering new targets for vaccines and therapeutics
Groot, A. S. D. (2006) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03720-7 · Cited by 153 · see citing works
Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein
Koren, E., Groot, A. S. D., Jawa, V., Beck, K. D., Boone, T., Rivera, D., Li, L., Mytych, D. T., Koscec, M., Weeraratne, D. K., et al. (2007) · Clinical Immunology · doi:10.1016/j.clim.2007.03.544 · Cited by 143 · see citing works
HLA-DRB1 polymorphism determines susceptibility to autoimmune thyroiditis in transgenic mice: definitive association with HLA-DRB1*0301 (DR3) gene.
Kong, Y. C., Lomo, L. C., Motte, R. W., Giraldo, A. A., Baisch, J., Strauß, G., Hämmerling, G. J., & David, C. S. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.3.1167 · Cited by 137 · see citing works
Safety and Immunogenicity of Tyrosinase DNA Vaccines in Patients with Melanoma
Wolchok, J. D., Yuan, J. D., Houghton, A. N., Gallardo, H. F., Rasalan, T. S., Wang, J., Zhang, Y., Ranganathan, R., Chapman, P. B., Krown, S. E., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300290 · Cited by 107 · see citing works
Rational Design of a Multiepitope Vaccine Encoding T-Lymphocyte Epitopes for Treatment of Chronic Hepatitis B Virus Infections
Depla, E., der Aa, A. V., Livingston, B. D., Crimi, C., Allosery, K., Brabandere, V. D., Krakover, J. D., Murthy, S., Huang, M. T. F., Power, S., et al. (2007) · Journal of Virology · doi:10.1128/jvi.01505-07 · Cited by 106 · see citing works
Untitled work
(2007) · PubMed · Cited by 100 · see citing works
Self-citation
Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII
Reding, M. T., Okita, D. K., Diethelm-Okita, B. M., Anderson, T. A., & Conti‐Fine, B. M. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00251.x · Cited by 99 · see citing works
From genome to vaccine—new immunoinformatics tools for vaccine design
Groot, A. S. D., & Berzofsky, J. A. (2004) · Methods · doi:10.1016/j.ymeth.2004.06.004 · Cited by 93 · see citing works
3D‐Epitope‐Explorer (3DEX): Localization of conformational epitopes within three‐dimensional structures of proteins
Schreiber, A. W., Humbert, M., Benz, A., & Dietrich, U. (2005) · Journal of Computational Chemistry · doi:10.1002/jcc.20229 · Cited by 92 · see citing works
A systematic bioinformatics approach for selection of epitope-based vaccine targets
Khan, A. M., Miotto, O., Heiny, A. T., Salmon, J., Srinivasan, K. N., Nascimento, E. J. M., Marques, E. T. A., Brusić, V., Tan, T. W., & August, J. T. (2006) · Cellular Immunology · doi:10.1016/j.cellimm.2007.02.005 · Cited by 90 · see citing works
High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection
Ahlers, J. D., Belyakov, I. M., Thomas, E. K., & Berzofsky, J. A. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13463 · Cited by 87 · see citing works
The Mapping and Reconstitution of a Conformational Discontinuous B-cell Epitope of HIV-1
Enshell‐Seijffers, D., Denisov, D. A., Groisman, B., Smelyanski, L., Meyuhas, R., Gross, G., Denisova, G. F., & Gershoni, J. M. (2003) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.09.002 · Cited by 85 · see citing works
The genetic basis of autoantibody production
Reveille, J. D. (2005) · Autoimmunity Reviews · doi:10.1016/j.autrev.2005.10.012 · Cited by 84 · see citing works
Analyzing Mycobacterium tuberculosis proteomes for candidate vaccine epitopes
McMurry, J. A., Sbai, H., Gennaro, M. L., Carter, E. J., Martin, W. D., & Groot, A. S. D. (2004) · Tuberculosis · doi:10.1016/j.tube.2004.09.005 · Cited by 83 · see citing works
Self-citation
Definition of a human T cell epitope from influenza A non-structural protein 1 using HLA-A2.1 transgenic mice
Man, S., Newberg, M. H., Crotzer, V. L., Luckey, C. J., Williams, N. S., Chen, Y., Huczko, E. L., Ridge, J. P., & Engelhard, V. H. (1995) · International Immunology · doi:10.1093/intimm/7.4.597 · Cited by 79 · see citing works
Enumerating Antigen-Specific T-Cell Responses in Peripheral Blood
Hobeika, A. C., Morse, M. A., Osada, T., Ghanayem, M., Niedzwiecki, D., Barrier, R. C., Lyerly, H. K., & Clay, T. M. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200501000-00008 · Cited by 72 · see citing works
Reduced Susceptibility of Recombinant Polyclonal Antibodies to Inhibitory Anti-Variable Domain Antibody Responses
Klitgaard, J. L., Coljee, V. W., Andersen, P. S., Rasmussen, L. K., Nielsen, L. S., Haurum, J., & Bregenholt, S. (2006) · Journal of Immunology · doi:10.4049/jimmunol.177.6.3782 · Cited by 71 · see citing works
Development of a Maturing T-Cell-Mediated Immune Response in Patients with Idiopathic Parkinson’s Disease Receiving r-metHuGDNF Via Continuous Intraputaminal Infusion
Tatarewicz, S. M., Wei, X. L., Gupta, S., Masterman, D. M., Swanson, S. J., & Moxness, M. S. (2007) · Journal of Clinical Immunology · doi:10.1007/s10875-007-9117-8 · Cited by 68 · see citing works
Naive and memory B cells in T-cell-dependent and T-independent responses
Zubler, R. H. (2001) · Springer Seminars in Immunopathology · doi:10.1007/s281-001-8167-7 · Cited by 64 · see citing works
HLA-DR4 (DRB1*0401) Transgenic Mice Expressing an Altered CD4-Binding Site: Specificity and Magnitude of DR4-Restricted T Cell Response
Pan, S., Trejo, T., Hansen, J., Smart, M. K., & David, C. S. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.2925 · Cited by 55 · see citing works
The structural requirements for class II (I‐Ad)‐restricted T cell recognition of influenza hemagglutinin: B cell epitopes define T cell epitopes
Graham, C. M., Barnett, B. C., Hartlmayr, I., Burt, D. S., Faulkes, R. A., Skehel, J. J., & Thomas, D. B. (1989) · European Journal of Immunology · doi:10.1002/eji.1830190317 · Cited by 51 · see citing works
Thyrotropin Receptor Epitopes and Their Relation to Histocompatibility Leukocyte Antigen-DR Molecules in Graves’ Disease
Inaba, H., Martin, W. D., Groot, A. S. D., Qin, S., & DeGroot, L. J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2537 · Cited by 48 · see citing works
A Comparison of Standard Immunogenicity Assays for Monitoring HIV Type 1 gag-Specific T Cell Responses in Ad5 HIV Type 1 gag Vaccinated Human Subjects
Tobery, T. W., Dubey, S. A., Anderson, K., Freed, D. C., Cox, K. S., Lin, J., Prokop, M. T., Sykes, K. J., Mogg, R., Mehrotra, D. V., et al. (2006) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2006.22.1081 · Cited by 39 · see citing works
Hotspot Hunter: a computational system for large-scale screening and selection of candidate immunological hotspots in pathogen proteomes
Zhang, G., Khan, A. M., Kellathur, S. N., Heiny, A. T., Lee, K. X., Kwoh, C. K., August, J. T., & Brusić, V. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-s1-s19 · Cited by 34 · see citing works
Immunogenicity of protein antigens : repertoire and regulation
Sercarz, E. E., & Berzofsky, J. A. (1987) · Medical Entomology and Zoology · Cited by 32 · see citing works
A repetitive sequence of Epstein–Barr virus nuclear antigen 6 comprises overlapping T cell epitopes which induce HLA-DR-restricted CD4+ T lymphocytes
Rajnavölgyi, É., Nagy, N., Thuresson, B., Dosztányi, Z., Simon, Á., Simon, I., Karr, R. W., Ernberg, I., Klein, E., & Falk, K. I. (2000) · International Immunology · doi:10.1093/intimm/12.3.281 · Cited by 26 · see citing works
The organization of human leucocyte antigen class I epitopes in HIV genome products: implications for HIV evolution and vaccine design
Zhang, C., Cornette, J. L., Berzofsky, J. A., & DeLisi, C. (1997) · Vaccine · doi:10.1016/s0264-410x(97)00040-6 · Cited by 24 · see citing works
DNA Immunization of HLA Transgenic Mice with a Plasmid Expressing Mycobacterial Heat Shock Protein 65 Results in HLA Class I- and II-Restricted T Cell Responses That Can Be Augmented by Cytokines
Charo, J., Sundbäck, M., Geluk, A., Ottenhoff, T. H. M., & Kiessling, R. W. (2001) · Human Gene Therapy · doi:10.1089/104303401750476285 · Cited by 23 · see citing works
Bioinformatics for study of autoimmunity
Petrovsky, N., & Brusić, V. (2006) · Autoimmunity · doi:10.1080/08916930601062437 · Cited by 22 · see citing works
Modelling the immunogenicity of therapeutic proteins using T cell epitope mapping.
Groot, A. S. D., Rayner, J., & Wj, M. (2003) · PubMed · Cited by 17 · see citing works
Application of HLA Class II Transgenic Mice to Study Autoimmune Regulation
Kong, Y.-C. M., Flynn, J. C., Banga, J. P., & David, C. S. (2007) · Thyroid · doi:10.1089/thy.2007.0196 · Cited by 16 · see citing works
Peptide-binding assays and HLA II transgenic Aβ° mice are consistent and complementary tools for identifying HLA II-restricted peptides
Depil, S., Angyalosi, G., Moralès, O., Delacre, M., Delhem, N., François, V., Georges, B., Hammer, J., Maillère, B., Auriault, C., et al. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.11.048 · Cited by 12 · see citing works

Flagged first, then by citations

Sorted by citations

Stability of Protein Pharmaceuticals: An Update
Manning, M. C., Chou, D. K., Murphy, B. M., Payne, R. W., & Katayama, D. S. (2010) · Pharmaceutical Research · doi:10.1007/s11095-009-0045-6 · Cited by 1,103 · see citing works
The immunogenicity of humanized and fully human antibodies
Harding, F., Stickler, M. M., Razo, J., & DuBridge, R. B. (2010) · mAbs · doi:10.4161/mabs.2.3.11641 · Cited by 743 · see citing works
Immunogenicity of Therapeutic Protein Aggregates
Moussa, E. M., Panchal, J. P., Moorthy, B. S., Blum, J. S., Joubert, M. K., Narhi, L. O., & Topp, E. M. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.002 · Cited by 533 · see citing works
Monoclonal antibody therapeutics: history and future
Buss, N. A. P. S., Henderson, S. J., McFarlane, M., Shenton, J. M., & de Haan, L. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.08.001 · Cited by 436 · see citing works
Therapeutic Proteins
Dimitrov, D. S. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-921-1_1 · Cited by 384 · see citing works
Impact of Product-Related Factors on Immunogenicity of Biotherapeutics
Singh, S. K. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22276 · Cited by 350 · see citing works
Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity
Sampei, Z., Igawa, T., Soeda, T., Okuyama-Nishida, Y., Moriyama, C., Wakabayashi, T., Tanaka, E., Muto, A., Kojima, T., Kitazawa, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057479 · Cited by 338 · see citing works
Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development
Ovacik, M., & Lin, K. (2018) · Clinical and Translational Science · doi:10.1111/cts.12567 · Cited by 299 · see citing works
T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation
Jawa, V., Cousens, L. P., Awwad, M., Wakshull, E., Kropshofer, H., & Groot, A. S. D. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.09.006 · Cited by 271 · see citing works
Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies
Ponce, R. A., Abad, L. W., Amaravadi, L. S., Gelzleichter, T. R., Gore, E. R., Green, J., Gupta, S., Herzyk, D. J., Hurst, C. H., Ivens, I. A., et al. (2009) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2009.03.012 · Cited by 271 · see citing works
Adnectins: engineered target-binding protein therapeutics
Lipovšek, D. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq097 · Cited by 242 · see citing works
The Key Role of Genomics in Modern Vaccine and Drug Design for Emerging Infectious Diseases
Seib, K. L., Dougan, G., & Rappuoli, R. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000612 · Cited by 200 · see citing works
“High‐risk” host cell proteins (HCPs): A multi‐company collaborative view
Jones, M., Palackal, N. T., Wang, F., Gaza‐Bulseco, G., Hurkmans, K., Zhao, Y., Chitikila, C., Clavier, S., Liu, S., Menesale, E. B., et al. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27808 · Cited by 163 · see citing works
Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice
Filipe, V., Jiskoot, W., Basmeleh, A., Halim, L. A., Schellekens, H., & Brinks, V. (2012) · mAbs · doi:10.4161/mabs.22066 · Cited by 159 · see citing works
Immunogenicity of Protein Pharmaceuticals
Dingman, R. K., & Balu‐Iyer, S. V. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.12.014 · Cited by 157 · see citing works
T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020
Jawa, V., Terry, F. E., Gokemeijer, J., Mitra‐Kaushik, S., Roberts, B., Tourdot, S., & Groot, A. S. D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01301 · Cited by 159 · see citing works
Emerging Vaccine Informatics
He, Y. O., Rappuoli, R., Groot, A. S. D., & Chen, R. T. (2010) · BioMed Research International · doi:10.1155/2010/218590 · Cited by 154 · see citing works
Therapeutic antibodies, vaccines and antibodyomes
Dimitrov, D. S. (2010) · mAbs · doi:10.4161/mabs.2.3.11779 · Cited by 141 · see citing works
Engineering the variable region of therapeutic IgG antibodies
Igawa, T., Tsunoda, H., Kuramochi, T., Sampei, Z., Ishii, S., & Hattori, K. (2011) · mAbs · doi:10.4161/mabs.3.3.15234 · Cited by 137 · see citing works
Immunogenicity assessment during the development of protein therapeutics
Rosenberg, A. S., & Sauna, Z. E. (2018) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12810 · Cited by 131 · see citing works
The Immunogenicity of Antibody Aggregates in a Novel Transgenic Mouse Model
Bessa, J., Boeckle, S., Beck, H., Buckel, T., Schlicht, S., Ebeling, M., Kiialainen, A., Koulov, A. V., Boll, B., Weiser, T. W., et al. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1627-0 · Cited by 125 · see citing works
Evaluating and mitigating the immunogenicity of therapeutic proteins
Sauna, Z. E., Lagassé, D., Pedras-Vasconcelos, J., Golding, B., & Rosenberg, A. S. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.05.008 · Cited by 118 · see citing works
Molecular engineering of antibodies for therapeutic and diagnostic purposes
Ducancel, F., & Muller, B. H. (2012) · mAbs · doi:10.4161/mabs.20776 · Cited by 108 · see citing works
Prediction of Immunogenicity of Therapeutic Proteins
Bryson, C. J., Jones, T. D., & Baker, M. (2010) · BioDrugs · doi:10.2165/11318560-000000000-00000 · Cited by 102 · see citing works
Therapeutic Antibodies Against Cancer
Adler, M. J., & Dimitrov, D. S. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.02.013 · Cited by 90 · see citing works
Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics
Wullner, D., Zhou, L., Bramhall, E., Kuck, A. J., Goletz, T. J., Swanson, S. J., Chirmule, N. B., & Jawa, V. (2010) · Clinical Immunology · doi:10.1016/j.clim.2010.06.018 · Cited by 86 · see citing works
Coupling of aggregation and immunogenicity in biotherapeutics: T- and B-cell immune epitopes may contain aggregation-prone regions
Kumar, S., Singh, S. K., Wang, X., Rup, B., & Gill, D. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0414-9 · Cited by 85 · see citing works
Protein unfolding strongly modulates the allergenicity and immunogenicity of Pru p 3, the major peach allergen
Toda, M., Reese, G., Gadermaier, G., Schulten, V. M. J., Lauer, I., Egger, M., Briza, P., Randow, S., Wolfheimer, S., Kigongo, V., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.04.020 · Cited by 83 · see citing works
CD4+ T Cell Epitope Discovery and Rational Vaccine Design
Rosa, D. S., Ribeiro, S. P., & Cunha‐Neto, E. (2010) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-010-0067-0 · Cited by 83 · see citing works
Low immunogenicity predicted for emerging avian-origin H7N9
Groot, A. S. D., Ardito, M. T., Terry, F. E., Levitz, L., Ross, T. M., Moise, L., & Martin, W. D. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.24939 · Cited by 74 · see citing works
Self-citation
Immunogenicity risk assessment of synthetic peptide drugs and their impurities
Groot, A. S. D., Roberts, B., Mattei, A. E., Lélias, S., Boyle, C., & Martin, W. D. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103714 · Cited by 73 · see citing works
A Descriptor Set for Quantitative Structure‐property Relationship Prediction in Biologics
Sankar, K., Trainor, K., Blazer, L. L., Adams, J., Sidhu, S. S., Day, T., Meiering, E. M., & Maier, J. K. X. (2022) · Molecular Informatics · doi:10.1002/minf.202100240 · Cited by 72 · see citing works
Human immunity in vitro — Solving immunogenicity and more
Giese, C., & Marx, U. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.12.011 · Cited by 62 · see citing works
Therapeutic proteins: developments, progress, challenges, and future perspectives
Kumar, V., Barwal, A., Sharma, N., Mir, D. S., Kumar, P., & Kumar, V. (2024) · 3 Biotech · doi:10.1007/s13205-024-03958-z · Cited by 62 · see citing works
Preclinical Models Used for Immunogenicity Prediction of Therapeutic Proteins
Brinks, V., Weinbuch, D., Baker, M., Dean, Y. D., Stas, P., Kostense, S., Rup, B. J., & Jiskoot, W. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1062-z · Cited by 60 · see citing works
Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody
Sampei, Z., Haraya, K., Tachibana, T., Fukuzawa, T., Shida-Kawazoe, M., Gan, S. W., Shimizu, Y., Ruike, Y., Feng, S., Kuramochi, T., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0209509 · Cited by 57 · see citing works
Living in LALA land? Forty years of attenuating Fc effector functions
Hale, G. (2024) · Immunological Reviews · doi:10.1111/imr.13379 · Cited by 55 · see citing works
OptMAVEn-2.0: De novo Design of Variable Antibody Regions against Targeted Antigen Epitopes
Chowdhury, R., Allan, M. F., & Maranas, C. D. (2018) · Antibodies · doi:10.3390/antib7030023 · Cited by 55 · see citing works
In vitro models for immunogenicity prediction of therapeutic proteins
Groell, F., Jordan, O., & Borchard, G. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.06.008 · Cited by 53 · see citing works
Analytical aspects of biosimilarity issues of protein drugs
Kálmán-Szekeres, Z., Olajos, M., & Ganzler, K. (2012) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2012.04.037 · Cited by 53 · see citing works
Translational strategies for development of monoclonal antibodies from discovery to the clinic
Tabrizi, M. A., Bornstein, G. G., Klakamp, S. L., Drake, A. W., Knight, R., & Roskos, L. K. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.12.008 · Cited by 53 · see citing works
Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters
Barbosa, M. D. F. S. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.01.011 · Cited by 52 · see citing works
Challenges and Opportunities in Absorption, Distribution, Metabolism, and Excretion Studies of Therapeutic Biologics
Xu, X., & Vugmeyster, Y. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9388-8 · Cited by 50 · see citing works
Immunogenicity of protein aggregates of a monoclonal antibody generated by forced shaking stress with siliconized and nonsiliconized syringes in BALB/c mice
Uchino, T., Miyazaki, Y., Yamazaki, T., & Kagawa, Y. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12765 · Cited by 49 · see citing works
Assessment of Therapeutic Antibody Developability by Combinations of In Vitro and In Silico Methods
Pérez, A.-M. W., Lorenzen, N., Vendruscolo, M., & Sormanni, P. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1450-1_4 · Cited by 40 · see citing works
Highlights on the Application of Genomics and Bioinformatics in the Fight Against Infectious Diseases: Challenges and Opportunities in Africa
Bah, S. Y., Morang’a, C. M., Kengne-Ouafo, J. A., Amenga-Etego, L. N.-K., & Awandare, G. A. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00575 · Cited by 42 · see citing works
Fasciola hepatica: The therapeutic potential of a worm secretome
Robinson, M. W., Dalton, J. P., O’Brien, B. A., & Donnelly, S. (2012) · International Journal for Parasitology · doi:10.1016/j.ijpara.2012.11.004 · Cited by 43 · see citing works
Can we prevent immunogenicity of human protein drugs?
Scott, D. W., & Groot, A. S. D. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.117564 · Cited by 41 · see citing works
MHC-associated peptide proteomics enabling highly sensitive detection of immunogenic sequences for the development of therapeutic antibodies with low immunogenicity
Sekiguchi, N., Kubo, C., Takahashi, A., Muraoka, K., Takeiri, A., Ito, S., Yano, M., Mimoto, F., Maeda, A., Iwayanagi, Y., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1518888 · Cited by 36 · see citing works
Humanization and Simultaneous Optimization of Monoclonal Antibody
Kuramochi, T., Igawa, T., Tsunoda, H., & Hattori, K. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-586-6_7 · Cited by 35 · see citing works
Nonclinical development of biopharmaceuticals
Baumann, A. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.09.013 · Cited by 33 · see citing works
Relationship between potential aggregation-prone regions and HLA-DR-binding T-cell immune epitopes: implications for rational design of novel and follow-on therapeutic antibodies
Kumar, S., Mitchell, M. A., Rup, B., & Singh, S. K. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23169 · Cited by 33 · see citing works
Monoclonal antibody based radiopharmaceuticals for imaging and therapy
Lin, M., Paolillo, V., Le, D., Macapinlac, H. A., & RAVIZZINI, G. C. (2021) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2021.100796 · Cited by 31 · see citing works
A structural in silico analysis of the immunogenicity of l-asparaginase from Escherichia coli and Erwinia carotovora
Belén, L. H., Lissabet, J. F. B., Rangel‐Yagui, C. D. O., Effer, B. R., Monteiro, G., Pessoa, A., & Farías, J. G. (2019) · Biologicals · doi:10.1016/j.biologicals.2019.03.003 · Cited by 31 · see citing works
Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products
Jankowski, W., Park, Y., McGill, J. R., Maraskovsky, E., Hofmann, M., Diego, V. P., Luu, B. W., Howard, T. E., Kellerman, R., Key, N. S., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018030452 · Cited by 30 · see citing works
Current In Vitro Assays for Prediction of T Cell Mediated Immunogenicity of Biotherapeutics and Manufacturing Impurities
Duke, B. R., & Mitra‐Kaushik, S. (2019) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-019-09412-5 · Cited by 30 · see citing works
Plant-made immunotoxin building blocks: A roadmap for producing therapeutic antibody-toxin fusions
Knödler, M., & Buyel, J. F. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107683 · Cited by 29 · see citing works
Biosimilars and biobetters as tools for understanding and mitigating the immunogenicity of biotherapeutics
Barbosa, M. D. F. S., Kumar, S., Loughrey, H. C., & Singh, S. K. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.07.003 · Cited by 30 · see citing works
Biosimilar recombinant follicle stimulating hormones in infertility treatment
Santi, D., & Simoni, M. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.925872 · Cited by 29 · see citing works
Universal Immunoassay Applied During Early Development of Large Molecules to Understand Impact of Immunogenicity on Biotherapeutic Exposure
Bautista, A., Salimi-Moosavi, H., & Jawa, V. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9403-0 · Cited by 29 · see citing works
ORFeome approach to the clonal, HLA allele-specific CD4 T-cell response to a complex pathogen in humans
Jing, L., McCaughey, S. M., Davies, D. H., Chong, T. M., Felgner, P. L., Rosa, S. C. D., Wilson, C. B., & Koelle, D. M. (2009) · Journal of Immunological Methods · doi:10.1016/j.jim.2009.05.011 · Cited by 27 · see citing works
Development of a FRET-Based Assay for Analysis of mAbs Internalization and Processing by Dendritic Cells in Preclinical Immunogenicity Risk Assessment
Wen, Y., Cahya, S., Zeng, W., Lin, J., Wang, X., Liu, L., Malherbe, L. P., Siegel, R. W., Ferrante, A., & Kaliyaperumal, A. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00444-1 · Cited by 28 · see citing works
Engineering therapeutic antibodies for patient safety: tackling the immunogenicity problem
Ulitzka, M., Carrara, S. C., Grzeschik, J., Kornmann, H., Hock, B. M., & Kolmar, H. (2020) · Protein Engineering Design and Selection · doi:10.1093/protein/gzaa025 · Cited by 27 · see citing works
Leishmania donovani Nucleoside Hydrolase (NH36) Domains Induce T-Cell Cytokine Responses in Human Visceral Leishmaniasis
Santos, M. L. B., Nico, D., de Oliveira, F. A., Barreto, A. S., de Sousa, I. P., Carrillo, E., Moreno, J., Luca, P. M. D., Morrot, A., Rosa, D. S., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00227 · Cited by 26 · see citing works
Models for evaluation of relative immunogenic potential of protein particles in biopharmaceutical protein formulations
Johnson, R., & Jiskoot, W. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23248 · Cited by 25 · see citing works
An integrated approach for characterizing immunogenic responses toward a bispecific antibody
Cohen, S., Chung, S., Spiess, C., Lundin, V., Stefanich, E. G., Laing, S. T., Clark, V., Brumm, J., Zhou, Y., Huang, C., et al. (2021) · mAbs · doi:10.1080/19420862.2021.1944017 · Cited by 24 · see citing works
Efficient production of bispecific antibody by FAST-Ig TM and its application to NXT007 for the treatment of hemophilia A
Koga, H., Yamano, T., Betancur, J., Nagatomo, S., Ikeda, Y., Yamaguchi, K., Nabuchi, Y., Sato, K., Teranishi-Ikawa, Y., Sato, M., et al. (2023) · mAbs · doi:10.1080/19420862.2023.2222441 · Cited by 23 · see citing works
Implementing a Clinical Immunogenicity Strategy using Preclinical Risk Assessment Outputs
Jawa, V., Maamary, J., Swanson, M. D., Zhang, S., & Montgomery, D. L. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.01.032 · Cited by 21 · see citing works
Humanization and Simultaneous Optimization of Monoclonal Antibody
Kuramochi, T., Igawa, T., Tsunoda, H., & Hattori, K. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8958-4_9 · Cited by 21 · see citing works
Improving TNF as a cancer therapeutic: Tailor‐made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects
Gerspach, J., Pfizenmaier, K., & Wajant, H. (2009) · BioFactors · doi:10.1002/biof.50 · Cited by 20 · see citing works
Bridging Innate and Adaptive Antitumor Immunity Targeting Glycans
Pashov, A. D., Monzavi‐Karbassi, B., Raghava, G. P. S., & Kieber‐Emmons, T. (2010) · BioMed Research International · doi:10.1155/2010/354068 · Cited by 18 · see citing works
Nanovesicles released by OKT3 hybridoma express fully active antibodies
Logozzi, M., Raimo, R. D., Properzi, F., Barca, S., Angelini, D. F., Mizzoni, D., Falchi, M., Battistini, L., & Fais, S. (2021) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1852401 · Cited by 18 · see citing works
Surface Plasmon Resonance for Therapeutic Antibody Characterization
Davidoff, S. N., Ditto, N. T., Brooks, A. E., Eckman, J. W., & Brooks, B. D. (2015) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-2617-6_3 · Cited by 16 · see citing works
J‐LEAPS peptide and LEAPS dendritic cell vaccines
Rosenthal, K. S., Taylor, P. R., & Zimmerman, D. H. (2011) · Microbial Biotechnology · doi:10.1111/j.1751-7915.2011.00278.x · Cited by 16 · see citing works
Immunoinformatics and reverse vaccinology methods to design peptide-based vaccines
Sharma, V., Singh, S., Ratnakar, T. S., & Prajapati, V. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90264-9.00029-5 · Cited by 14 · see citing works
Pioneering Use of the Cloud for Development of Collaborative Drug Discovery (CDD) Database
Ekins, S., Hohman, M. M., & Bunin, B. A. (2011) · doi:10.1002/9781118026038.ch21 · Cited by 14 · see citing works
Advances in Predicting and Manipulating the Immunogenicity of Biotherapeutics and Vaccines
Flower, D. R. (2009) · BioDrugs · doi:10.2165/11317530-000000000-00000 · Cited by 13 · see citing works
Product-Related Factors and Immunogenicity of Biotherapeutics
Krishna, M. (2019) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-019-09423-2 · Cited by 12 · see citing works
Immunogenicity assessment of fungal l-asparaginases: an in silico approach
Belén, L. H., Lissabet, J. F. B., Rangel‐Yagui, C. D. O., Monteiro, G., Pessoa, A., & Farías, J. G. (2020) · SN Applied Sciences · doi:10.1007/s42452-020-2021-z · Cited by 12 · see citing works
Insights on the Formulation of Recombinant Proteins
Ribeiro, R., Abreu, T. R., Silva, A. C., Gonçalves, J., & Moreira, J. N. (2019) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2019_119 · Cited by 11 · see citing works
Characterization of the robust humoral immune response to GSK2618960, a humanized anti-IL-7 receptor monoclonal antibody, observed in healthy subjects in a Phase 1 study
Liao, K., Chen, K., Brett, S. J., Gehman, A., Schwartz, A. M., Gunn, G. R., & DeWall, S. L. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249049 · Cited by 8 · see citing works
Formulation development of small and large volume injections
Kamat, M. S., & DeLuca, P. P. (2012) · CRC Press eBooks · doi:10.3109/9781420086447-6 · Cited by 6 · see citing works
Antibody Fragments Humanization: Beginning with the End in Mind
Aubrey, N., & Billiald, P. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8958-4_10 · Cited by 6 · see citing works
Japanese Regulatory Perspective on Immunogenicity
Hayakawa, T., & Ishii‐Watabe, A. (2011) · doi:10.1002/9781118075685.ch4 · Cited by 6 · see citing works
Therapeutic antibody discovery
Hoover, J. M., Prinslow, E. G., Teigler, J. E., Truppo, M. D., & LaPorte, S. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820007-0.00023-4 · Cited by 4 · see citing works
Preclinical Immunogenicity Risk Assessement of Biotherapeutics
Jones, T. D., Karle, A. C., & Baker, M. (2015) · CRC Press eBooks · doi:10.1201/b19023-6 · Cited by 3 · see citing works
Sensitization to food or inhalant allergens in pediatric patients. Clinical usefulness of first-level panel tests for specific IgE.
Altrinetti, V., Salmaso, C., Montagna, P., Castellano, E., Cosentino, C., Pesce, G., & Bagnasco, M. (2003) · PubMed · Cited by 3 · see citing works
A novel in silico platform combining data-driven and physics-based models for protein formulation developability assessment
Arsiccio, A., Mutschler, H., Pedro, A. S., Pabstmann, T., Helbig, C., Brandstetter, D., Cerasoli, E., Hawe, A., & Menzen, T. (2026) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2026.104196 · Cited by 2 · see citing works
Immunogenicity Lessons Learned from the Clinical Development of Vatreptacog Alfa, A Recombinant Activated Factor VII Analog, in Hemophilia with Inhibitors
Lamberth, K., Weldingh, K. N., Ehrenforth, S., Chéhadé, M. R., & Østergaard, H. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2016_1 · Cited by 2 · see citing works
Crystal structure of ultra-humanized anti-pTau Fab reveals how germline substitutions humanize CDRs without loss of binding’
Brinth, A. R., Svenson, K., Mosyak, L., Cunningham, O., Hickling, T. P., & Lambert, M. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-12838-6 · Cited by 2 · see citing works
Safety Assessment Strategies and Predictive Safety of Biopharmaceuticals and Antibody Drug Conjugates
Horner, M. J., Hinrichs, M. J., & Buss, N. A. P. S. (2016) · doi:10.1002/9781119053248.ch3 · Cited by 2 · see citing works
Biopharmaceutics of NCEs and NBEs
Agoram, B. M., Sagawa, K., Shanker, R., & Singh, S. K. (2012) · CRC Press eBooks · doi:10.3109/9781420086447-4 · Cited by 1 · see citing works
In Vitro Assays for Assessing Potential Adverse Effects of Cancer Immunotherapeutics
Li, J., Mitra, M. S., & Rao, G. K. (2020) · Methods in pharmacology and toxicology · doi:10.1007/978-1-0716-0171-6_12 · Cited by 1 · see citing works
Therapeutic antibody development—Remington chapter
Geist, B. J., Zheng, S., & Xu, Y. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820007-0.00024-6 · Cited by 1 · see citing works
DELETION OF ANTIBODY ENCODED TOLEROGENIC SIGNALS TO IMPROVE A DENDRITIC CELL TARGETED VACCINE DELIVERY PLATFORM SYSTEM
Aguirre, D. (2014) · doi:10.23860/thesis-aguirre-danielle-2014
Conditions for safe and effective ADEPT treatment
Wilkins, D. K. (2010) · UCL Discovery (University College London)
Análise da imunogenicidade de uma vacina de DNA codificando epitopos CD4 promíscuos e conservados do HIV-1 em camundongos BALB/c e transgênicos para moléculas de HLA classe II
Ribeiro, S. P. (2010) · doi:10.11606/t.5.2010.tde-22092010-120821
Prognostic immune markers for chronic allograft injury inrenal transplant recipients
Jham, S. (2017) · University of Birmingham Institutional Research Archive (University of Birmingham)
Sciences, réseaux et cognition après le déluge
Ganascia, J. (2014) · CNRS Éditions eBooks · doi:10.4000/books.editionscnrs.19990
Formulation strategy and tactics for mAbs: not all mAbs are the same
Bee, J. S., Shah, A., Bishop, S. M., & Remmele, R. L. (2015) · doi:10.4155/fseb2013.14.321

Preclinical Models Used for Immunogenicity Prediction of Therapeutic Proteins
Brinks, V., Weinbuch, D., Baker, M., Dean, Y. D., Stas, P., Kostense, S., Rup, B. J., & Jiskoot, W. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1062-z · Cited by 60 · see citing works
Nonclinical Immunogenicity Risk Assessment of Therapeutic Proteins
Tourdot, S., & Hickling, T. P. (2019) · Bioanalysis · doi:10.4155/bio-2018-0246 · Cited by 39 · see citing works
OVERVIEW OF PRE-CLINICAL TECHNIQUES FOR PREDICTING THE IMMUNOGENICITY OF THERAPEUTICS IN DRUG DEVELOPEMENT
Musanabaganwa, C., & Byiringiro, F. (2014) · Bioline International (Bioline International)
Strategies for preclinical immunogenicity assessment of protein therapeutics.
Stas, P., & Lasters, I. (2009) · PubMed · Cited by 26 · see citing works
Untitled work
(2007) · PubMed · Cited by 100 · see citing works
Self-citation

Authors: DEGROOT, A., MCMURRY, J., & MOISE, L.
Affiliations: University of Rhode Island (US)
Corresponding author: DEGROOT, A
MOISE, L
ORCID: MCMURRY, J
MOISE, L
Venue: Current Opinion in Pharmacology
Publisher: Elsevier BV
Published: 2008-10
Volume: 8
Issue: 5
Pages: 620-626
ISSN: 1471-4892 (ISSN-L)
DOI: 10.1016/j.coph.2008.08.002
OpenAlex: W2092720388
Cited by: 109
References: 55
Citations by year: 2026: 4 · 2024: 3 · 2023: 2 · 2022: 5 · 2021: 7 · 2020: 8 · 2019: 5 · 2018: 10 · 2017: 5 · 2016: 2 · 2015: 5 · 2014: 4 · 2013: 6 · 2012: 14
FWCI: 3.84
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Current Opinion in Pharmacology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
Keywords: immunogenicity prediction, therapeutic proteins, antidrug antibodies, in silico prediction tools, preclinical drug development, pharmacokinetics, adverse drug reactions, neutralizing antibodies
MeSH terms: Animals, Epitopes, B-Lymphocytes, Computer Simulation, Drug Evaluation, Preclinical, Humans, Mice, Transgenic, Recombinant Proteins, T-Lymphocytes, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks